Second International

BioArrays-2004-New York Meeting

“Biochips in Diagnostics, Industrial Genomics & Proteomics: Systemomics™ Approaches”
At Holiday Inn Midtown, 440 West 57th Street, New York City, New York, USA
(Few Blocks from Central Park and Times Square)
On
July 26-27, 2004

Target Audience:	300
Total Speaker Presentations:	30
Total Poster Presentations:	30
Total Exhibit Booths:	30

 

 

 

 

 

 

AGENDA/SPEAKERS

Click Here for the Final Agenda(.pdf)

Monday, July 26, 2004
7.00 A.M: Registration Open

7.30 – 9.00 A.M: Continental Breakfast
Technology Session I (consists of 3 lectures)

Scientific Sessions Start at 9.15 A.M and ends at 5.45 P.M.

Tuesday, July 27, 2004
7.30 – 9.00 A.M: Continental Breakfast
Technology Session II (consists of 3 lectures)

Scientific Sessions Start at 9.15 A.M and ends at 5.45 P.M.

The actual agenda will be updated. Please visit again.

Scientific Advisory Committee:

- K. Appasani, PhD., MBA. GeneExpression Systems, Inc.
- J. Ju, PhD. Associate Professor, Columbia University College of    Physicians & Surgeons
- J. L. Walewski, PhD. Assistant Professor, Mount Sinai School of Medicine,    NYU
- J. LaBaer, MD,PhD. Harvard Institute of Proteomics, Harvard Medical School  

Inaugural Speaker:

                 

Eric Kandel, MD.
Nobel Laureate 2000 (Medicine & Physiology)
Columbia University College of Physicians & Surgeons
New York, NY

Keynote Speaker:

John Burczak, PhD.
Vice President of Development
GE HealthCare (Formerly Amersham Biosciences)
Piscataway, NJ

Key Presentations: (Will be updated from time-to-time)

Legionella pneumophila: From genome to transcriptome
James J. Russo, Ph.D. Research Scientist and Associate Head Sequencing and Chemical Biology, Columbia Genome Center, Columbia University, New York, NY

Zooming In: Moving from Genome-Wide Expression Profiling to High-Throughput Fingerprint Screening
Jay P. Tiesman, Ph.D. Genomics Group Leader, Procter & Gamble, Cincinnati, OH

Noninvasive diagnosis of liver cirrhosis using DNA-sequencer-based total serum protein glycomics
Roland Contreras, PhD. Professor of Molecular Biology, Ghent University, Belgium

Application of Gene Expression Profiling to drug discovery in Regeneron Pharmaceuticals
Yi Wei, Ph.D. Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. Tarrytown, NY

Self-Assembling Protein Microarrays
Joshua LaBaer, M.D., PhD. Director, Harvard Institute of Proteomics, Harvard Medical School, Cambridge, MA

Expression Profiling in Support of Compound Selection
Petra Ross-Macdonald, PhD. Senior Research Investigator, Bristol Myers-Squibb, Princeton, NJ

Semiconductor based in situ synthesis of oligonucleotide microarrays
Andy McShea, PhD. Director, Applied Science, CombiMatrix Inc. Mukileto, WA

Integrative Approaches to Cancer: Biology, Biomarkers, and Bioinformatics
Arul M. Chinnaiyan, MD., PhD. Assistant Professor of Pathology and Urology, University of Michigan Medical School, Ann Arbor, MI

Transplantation Biomarker Discovery and Validation
Yihong Yao, PhD. Abbott Bioresearch Center, Worcester, MA

Molecular characterization of aging in human prefrontal cortex
Loubna Erraji-Benchekroun, PhD. Research Fellow, New York State Psychiatric Institute, Columbia University, New York, NY

Microarray Analysis of HCV-Related Liver Diseases and HCV Model Systems
Jose Walewski, PhD. Assistant Professor of Medicine, The Mount Sinai Hospital and Mount Sinai School of Medicine, New York, NY


Exploring the use of Gene Expression-based in vivo Pharmacodynamic Assays
Michael Mallamaci, Ph.D. Principal Scientist, AstraZeneca Pharmaceuticals, Wilmington, DE

Gene expression profiling for biomarker discovery
Kazuhiko Uchida, MD, PhD. Associate Professor, University of Tsukuba & AIST, JAPAN

Photocleavable Fluorescent Nucleotides for DNA Sequencing on a Chip Constructed by Click Chemistry
Jingyue Ju, PhD. Associate Professor & Head of Columbia Genome Center
Columbia University College of Physicians & Surgeons, New York, NY

Slide surface chemistry holds the key to a reliable and reproducible microarray analysis
Muhammad A. Lodhi, PhD. Director, Diagnostics & Drug Discovery, SurModics, Inc. Eden Prairie, MN

Microarrays and Diagnostics in the Academic Environment: The Future of Technology, Bioinformatics and Medicine
Andrew Brooks, PhD. Assistant Professor and Director of Functional Genomics Center, University of Rochester Medical School, Rochester, NY

A Next Generation Slide Processing Platform for IHC, ISH, and Microarray Applications
Anis H. Khimani, Ph.D. Director, Marketing, Ventana Medical Systems, Inc. Tucson, AZ

The LDL Receptor-Related Protein 5 (LRP-5) Gene: Genomic Approaches for the Development of New Targets for Osteoporosis
Eugene L. Brown, PhD. Senior Director, Expression Profiling Sciences, Wyeth Research, Cambridge, MA

Multiplex Protein Quantification using SearchLight? Proteome Arrays
Scott Van Arsdell, PhD. Associate Director of Research, Pierce Biotechnology, Inc. Woburn, MA

High Throughput MicroArrays with Nanopin M ceramic capillary pins and Ez-Rays 96 well microplates
Ezra S. Abrams, PhD. Director, Matrix Technologies Corp. Hudson, NH


Diagnostic Applications of Array Comparative Genomic Hybridization
Edward Chait, PhD. CEO, Spectral Genomics, Inc. Houston, TX


Reverse Microarray of Depleted Human Plasma Significantly Enhances Low Abundant Protein Detection and Allows Disease Specific Protein Measurement
Sunny Tam, Ph.D. Manager, Charles River Proteomic Services, Worcester, MA


TBA
Dennis McCormac, Ph.D. Director of Product Marketing, Iobion Informatics, LLC, Toronto, Canada

Abstracts

Steps Toward a Molecular Biology of Memory Storage
Eric Kandel, MD. Nobel Laureate 2000 (Physiology or Medicine), University Professor, Senior Investigator of Howard Hughes Medical Institute, Founding Director of Center for Neurobiology & Behavior, Columbia University College of Physicians and Surgeons, New York, NY

I would like to consider two aspects of the molecular biology of memory storage. First I will try to give you an overview of a conserved core signaling mechanism that is used in a variety of different contexts to convert short-term memory to long-term memory. Second, I would like to focus on a potential mechanism that can contribute to the persistence of memory storage over a period of days, weeks or longer.


Expression Profiling in Support of Compound Selection
Petra Ross-Macdonald, PhD. Senior Research Investigator, Bristol Myers-Squibb, Princeton, NJ

Pharmaceutical compounds are subjected to an increasingly stringent traige process, and yet still may have hidden liabilities of selectivity that can be lead to expensive failures later in development. We are analyzing the gene expression profiles of treated cells to uncover such differences, providing an additional and novel means of characterizing and prioritizing compounds. We will discuss examples of this approach in several drug discovery programs.

Noninvasive diagnosis of liver cirrhosis using DNA-sequencer-based total serum protein glycomics
Roland Contreras, PhD. Professor of Molecular Biology, Department of Molecular Biomedical Research, Ghent University and Flanders Interuniversity Institute for
Biotechnology, Technologiepark 927, B-9052 Zwijnaarde, Belgium

Nico Callewaert1°, Hans Van Vlierberghe2, Annelies Van Hecke1, Wouter Laroy1, Joris Delanghe3 and Roland Contreras1

1 Department of Molecular Biomedical Research, Ghent University and Flanders Interuniversity Institute for Biotechnology, Technologiepark 927, B-9052 Zwijnaarde, Belgium
2 Department of Gastroenterology and Hepatology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
3 Department of Clinical chemistry, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
° Current address: Swiss Federal Institute of Technology (ETH), Schmelzbergstrasse 7, CH-8092 Zürich, Switzerland.

We developed a 'clinical glycomics' method that uses a PCR thermocycler and a DNA sequencer/fragment analyzer to rapidly generate high-resolution profiles of the N-glycan post-translational modifications present on the proteins in patient's serum (see the Figure of this abstract). We have found that the serum N-glycome yields a biomarker that diagnoses mild liver cirrhosis with 90% efficiency (and advanced liver cirrhosis with 100% efficiency). Highly specific serum biomarkers such as the one described here are very valuable, as they can help to obviate the biopsy need in a lot of cirrhosis patients. Moreover, this biomarker could eventually be used in routine follow-up of chronic liver disease patients, to yield an early warning signal that cirrhosis has developed and that complications (amongst others: hepatocellular carcinoma) might arise. Our biomarker can easily be implemented in the majority of the existing molecular diagnostics laboratories at low cost.

Legionella pneumophila: From genome to transcriptome
James J. Russo, Ph.D. Associate Head of Sequencing and Chemical Biology
Columbia Genome Center, New York, NY

We recently sequenced the genome of Legionella pneumophila, the causative agent of Legionnaires’ disease. The 3.4 Mb genome was mined for potential virulence genes, critical transporters, unexpected metabolic pathways, and unstable elements. We also identified sets of genes common to intracellular pathogens and Legionella-specific expansions of critical genes occurring singly in other bacteria. We produced a microarray based on all the predicted genes that has been used for expression studies on bacterial growth in wt and rpoS null strains; BAC hybridization studies to confirm the genome sequence assembly; and genome-to-genome DNA hybridization studies to understand evolutionary relationships and lifestyles.

A Next Generation Slide Processing Platform for IHC, ISH, and Microarray Applications
Anis H. Khimani, Ph.D. Director, Marketing, MDS, Ventana Medical Systems, Inc. Tucson, AZ
.
Automated slide processing provides standardization and reliability in applications such as immunohistochemistry (IHC), in situ hybridizations (ISH), and microarray hybridizations, including tissue microarrays. Ventana’s Discovery® system has offered complete walk-away automation for assay development in target identification and validation, and in preclinical toxicology and biomarker development and validation. The new Discovery® XT system enhances the assay development and validation process with increased capacity and greater consistency. Data from these applications on numerous model systems will be presented.

Self-Assembling Protein Microarrays
Joshua LaBaer, M.D., Ph.D. Director, Institute of Proteomics, Harvard Medical School, Cambridge, MA

Protein microarrays provide a powerful tool for the study of protein function. However, they are not widely used in part because of the challenges in producing proteins to spot on the arrays. We generated protein microarrays by printing cDNAs onto glass slides and then translating target proteins with mammalian reticulocyte lysate. Epitope tags fused to the proteins allow them to be immobilized in situ. This obviates the need to purify proteins, avoids protein stability problems during storage and captures sufficient protein for functional studies. We used the technology to map pairwise interactions among 29 human DNA replication initiation proteins, to recapitulate the regulation of Cdt1 binding to select replication proteins, and to map its geminin binding domain.

Molecular characterization of aging in human prefrontal cortex
L. Erraji-Benchekroun, PhD. Department of Psychiatry, Columbia University and Department of Neuroscience, New York Sate Psychiatric Institute, New York, NY

L. Erraji-Benchekroun1,2, H. Galfalvy1, V. Arango1,2, M.D. Underwood1,2, P. Smyrniotopoulos2, P. Pavlidis3, J.J. Mann1,2, and E. Sibille1,2.
1. Dept. of Psychiatry, Columbia University, New York, NY, USA, 2. Dept. of Neuroscience, NYSPI, New York, NY, USA, 3. Genome Center, Columbia University, New York, NY, USA

Aging leads to morphological and functional changes in the brain, and is associated with increased risk for numerous psychiatric and neurological disorders. To identify normal age-related transcriptional changes that occur in the human brain, we used profiled gene expressions in two prefrontal cortical areas that are involved in higher cognitive processes, Brodmann areas 9 and 47. We identified a “molecular signature” of aging, consisting of changes in expression levels of at least 540 genes that were progressive throughout the adult life. By combining estimates of cellular origins of expression with large-scale functional analysis we found that age-upregulated transcripts were mostly of glial origin and related to inflammation, cellular defenses, structural filaments, chromatin structure and signal transduction. Genes downregulated with age revealed selective changes in neuronal systems, including transcripts whose products were associated with voltage-gated channel activity, calcium regulation, G-protein-coupled receptor signaling and neuropeptide activity. Our results provide robust molecular markers of normal brain aging.

Supported by: MH62185, MH40210, 5 T32 MH20004/05 & American Foundation for Suicide Prevention

Application of Gene Expression Profiling to drug discovery in Regeneron Pharmaceuticals
Yi Wei, Ph.D. Regeneron Pharmaceuticals, Inc. Tarrytown, NY

Regeneron is a biophamaceutical company that discovers and develops protein therapeutics for the treatment of various diseases. We have established a microarray facility to support different research initiatives in Regeneron, using Agilent oligonucleotide microarrays. We are going to present several examples of the contributions of gene expression profiling to drug discovery in Regeneron. First, gene expression profiling is used to phenotype knock-out mice coming out of our Velocigene program, a high throughput system of producing knock-out mice. Second, gene expression profiling is used to elucidate the molecular mechanisms underlying angiopoietin-1, an essential regulator of vascular development. And last, gene expression profiling is used to look for new targets in angiogenesis therapy for cancer.

Multiplex Protein Quantification using SearchLight? Proteome Arrays
Scott Van Arsdell, PhD. Associate Director of Research, Pierce Biotechnology, Inc. Woburn, MA

SearchLight? Proteome Arrays are multiplexed sandwich ELISAs for the quantitative measurement of 2 to 25 proteins per well offering excellent sensitivity, small sample volume, compatibility with plate-based equipment, and a broad menu of proteins. This presentation will review the SearchLight technology, the array configurations currently available, and the instrumentation and array software utilized to generate results. In-house data from various stimulation and time course studies will be presented. General performance data exhibiting the specificity, accuracy, and reproducibility of the arrays and the various ways that the SearchLight? technology can be accessed (analysis system, custom array development, and sample testing services) will also be discussed.

High Throughput MicroArrays with Nanopin M ceramic capillary pins and Ez-Rays 96 well microplates
Ezra S. Abrams, PhD. Director, Matrix Technologies Corp. 22 Friars Drive, Hudson, NH

Ezra S Abrams; C. Boles; J. Melo; S. Mielewczyk; B. Patterson; B. Stone
Matrix Technologies, 22 Friars Drive, Hudson NH
The Nanopin M is a ceramic capillary pin designed for contact printing of microarrays. With a closed capillary design, several hundred spots can be printed from each source visit, and speed is further increased because little or no pre-blotting is needed. Nanopin M pins have good pin to pin reproducibility, due to the precise manufacturing process, and new pins can be added to a set of “old” pins at any time, as the hard ceramic material does not wear or deform. We have used Nanopin M ceramic pins to print DNA microarrays on both slides (ez-rays amino-silane or ez-rays universal) and on ez-rays plates, which are 96 well glass bottom microplates with ez-rays universal coating. The combination of ceramic pins and plates allows the researcher to print, in a single run, >1,000 arrays, each with up to several hundred probes.

Gene expression profiling for biomarker discovery
Kazuhiko Uchida, MD., PhD. Associate Professor, University of Tsukuba and Clinical Bioinfomatics Research Initiative, AIST, Tsukuba, Ibaraki, JAPAN

Cancer diagnostics and therapeutics are often based on clinically relevant markers that are expressed specifically in a malignant tissue at levels higher than in normal tissue. Gene expression profiles for papillary thyroid carcinoma, normal thyroid tissue, and healthy peripheral blood cells using a human 4K-gene in-house cDNA microarray and GeneChip U133 45K array and immunohistochemistry of the up-regulated gene products identified PDGF as a protein that are specifically expressed at high levels in thyroid neoplasms. Thus, expression profile analysis using a microarray followed by an immunohistochemical study can be used to facilitate the development of molecular biomarkers for cancer.

Photocleavable Fluorescent Nucleotides for DNA Sequencing on a Chip Constructed by Click Chemistry
Jingyue Ju, PhD. Associate Professor & Head of Columbia Genome Center and Department of Chemical Engineering, Columbia University College of Physicians & Surgeons, New York

DNA sequencing by synthesis on a solid surface during polymerase reaction offers a new paradigm to decipher DNA sequences. We report the design of such a novel DNA sequencing system using chemical and molecular engineering approaches. The design rationale of the system is to use 4 distinct fluorescent emissions to code for the identity of the 4 nucleotides (A, C, G, T) during DNA polymerase reaction. We have designed and synthesized 4 photocleavable fluorescent nucleotides for such a system and established a covalent and chemoselective 1,3-dipolar azide-alkyne cycloaddition coupling chemistry for immobilizing DNA on a chip. DNA sequencing results from such a system will be presented.

Exploring the use of Gene Expression-based in vivo Pharmacodynamic Assays
Michael Mallamaci, PhD. Group Leader, Principal Scientist, AstraZeneca Pharmaceuticals, Wilmington, DE

A major component of the drug discovery process is the use of animal models to demonstrate in vivo efficacy and to optimize basic in vivo drug properties. Unfortunately, in many cases the number of compounds that can be tested is limited by the time and expense associated with the assays; this is especially true of CNS models with a behavioral readout. What is needed is a primary in vivo assay that employs a simple but reliable marker that measures a drug effect in the CNS. This assay can be used to establish many of the pharmacodynamic properties of the compound prior to in vivo functional testing. The use of both global and specific quantitative gene expression profiling platforms for the development and implementation of in vivo pharmacodynamic assays will be discussed.

Reverse Microarray of Depleted Human Plasma Significantly Enhances Low Abundant Protein Detection and Allows Disease Specific Protein Measurement
Sunny Tam, Ph.D. Manager, Charles River Proteomic Services, Worcester, MA

We have developed a high-throughput depletion protocol using chicken IgY antibodies (GenWay Biotech) that are capable of removing abundant proteins such as albumin or IgG from plasma and serum across multiple mammalian species. By using the IgY antibodies in an automated liquid chromatography system, the depleted sera and the abundant protein associated complexes can be microarrayed and archived using the Zeptosens reverse array platform. The depletion methodology also further increases the detection range of low abundant proteins, such as antithrombin III and interleukins. Furthermore, by lowering the protein complexity of the samples through depletion, a more accurate disease specific protein measurement can be obtained.

Diagnostic Applications of Array Comparative Genomic Hybridization
Edward Chait, PhD. CEO, Spectral Genomics, Inc. Houston, TX

Johnson, Robert C., Xin Yan Lu, Scott Hutto, Jae-weon Kim and Edward Chait. Spectral Genomics, Inc., Houston, TX

Array Comparative Genomic Hybridization using Bacterial Artificial Chromosomes (BACs) printed on glass slides provides a means of evaluating chromosomal structure changes across the entire genome in one assay. Spectral Genomics, Inc. manufactures SpectralChip™ that contains 2600 BACs printed in duplicate for research purposes and its Constitutional Chip™ containing 464 BACs printed in triplicate for research in the area of constitutional syndromes. These microarrays have been used to detect copy number changes in tumor samples at a resolution of approximately 1Mb and thereby provide a much more sensitive method to identify chromosomal changes than conventional cytogenetics approaches. The microarrays also have utility in detecting deletions and amplifications diagnostic for a wide range of syndromes. The Constitutional chip™ is specifically designed for identification of a number of microdeletion syndromes traditionally detected by FISH assays. In essence, the microarrays perform hundreds or thousands of FISH assays at one time and thereby act as a high capacity screening tool for detection of disease associated with DNA structural changes.

Zooming In: Moving from Genome-Wide Expression Profiling to High-Throughput Fingerprint Screening
Jay P. Tiesman, PhD. Procter & Gamble, Miami Valley Labs, PO Box 538707, Cincinnati, OH 45252-8707

Jay P. Tiesman, Suzanne M. Torontali, Kenton D. Juhlin, M. Lynn Jump1, Brian D. Richardson2, Kerry G. Oliver3, George P. Daston, Jorge M. Naciff
Procter & Gamble, Miami Valley Labs, Cincinnati, OH
1Procter & Gamble, Health Care Research Center, Mason, OH
2Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3Radix BioSolutions, Georgetown, TX

A primary goal of genome-wide expression profiling is to identify subsets of gene transcripts that can be associated with specific biological conditions. Once these gene expression “fingerprints” have been elucidated, they can be used in screening assays to identify molecules that induce similar gene expression changes. To increase the throughput of these screening assays, we have optimized the development of a bead-based, flow-cytometric platform that allows the high-throughput screening of up to 100 transcripts per sample in a 96-well plate format. We have achieved detection levels down to 1 attomole per analyte, which allows the detection of rare messages in complex cRNA samples. This presentation will describe the development of this assay as well as outstanding technical issues currently being addressed. It is anticipated that this technology will be a useful secondary screening platform for high-throughput gene expression fingerprinting.

Slide Surface Chemistry Holds the Key to Reliable and Reproducible Microarray Analyses
Muhammad A. Lodhi, PhD. Director of Diagnostics and Drug Discovery, SurModics, Inc. Eden Prairie, MN

Muhammad A. Lodhi and Gary W. Opperman, Diagnostics and Drug Discovery, SurModics, Inc. Eden Prairie, MN

Microarray analysis is characterized by simultaneous detection of multiple hybridizations and/or molecular interactions of surface-bound probes to free-floating targets in solution. Due to the complex nature of microarrays, each component, from substrate to surface chemistry and from probe content to the detection system, plays a critical role in the final outcome of the analyses. Recently, several individual laboratories and consortia have run comparisons on commercial microarrays and found variable, and in some cases, contradictory results. In this presentation, the contribution of surface chemistry to the overall variability of the results will be discussed.

Transplantation Biomarker Discovery and Validation
Yihong Yao, PhD. Senior Scientist, Abbott Bioresearch Center, Worcester, MA

Wider Implementation of biomarker strategies promises to help meet unmet medical needs as well as enable more economical clinical development. Biomarkers fall into many classes that can be used to meet different needs. Surrogate end points are biomarkers predicting efficacy, with proper validation these can be used to support FDA registrations. Phenotypic and genotypic biomarkers can be used to classify patient populations and indicate appropriate treatments or susceptible populations. Pharmacodynamic biomarkers (PDBMs) can be used to measure acute target inhibition without measuring efficacy. These biomarkers are potentially useful in determining dose during clinical trials and after approval. We have taken a microarray approach to discovering PDBM’s useful for monitoring compounds used to prevent organ graft rejection. Using a panel of normal subjects and T cell activation models we have identified a set of markers that respond to proprietary and currently marketed compounds such as FK506. We will present details of the processes leading to the discovery and validation of these markers.

Please contact if you are interested in speaking in the scientific or Technology workshops of this meeting.

• Six speakers will be chosen from Academia includes Rockefeller, Cornell, Columbia, NYU and Sloan Kettering.
• Six speakers will be chosen from the Biotech industry.
• Ten speakers will be chosen from the Pharmaceutical industry.

Panel Discussion on July 27th with experts from:
- Venture Capital Firm, New York, NY
- Technology Licensing Manager from NYC University, New York, NY
- A Patent Attorney from Intellectual Property Law Firm, New York, NY
- Professional Science/Business Journalists
- Professional Business Journalist (either from NY Times or Wall Street   Journal or Business Week)
- Selected Academic Speaker from the meeting.
- Selected Industry Speaker/Executive from the meeting.

Exhibitors are welcome to reserve their booth space.

GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781) 891-8234
E-mail: Genexpsys@expressgenes.com
www.expressgenes.com


BioArrays-2003-New York Meeting Testimonials

“If I compare the presentations at BioArray 2003 with any innovative technology meetings, they would rank among the top work in the field.” - Prof. Francis Barany, Cornell and Rockefeller University

“It was very well organized and a productive meeting for me.” – Dr. Eric Eastman, CSO, MetriGenix

“It is very nicely integrated scientific meeting to demonstrate the new technology with very limited industrial marketing compared to any other meetings.” - Dr. Charles Tackney, Director, Ortho-Clinical Diagnostics and Johnson & Johnson

“This is an excellent and relevant meeting for me to learn the basics and apply in the clinic.” - Prof. Joe Lunec, Univ. of Leicester, UK

“Truly a fascinating theme to gather experts in the field.” - Prof. Victor Barsky, Russian Academy of Sciences, Moscow, Russia

“Very well balanced meeting chosen to have excellent speakers in the field, and gave me full understanding of array technology and how it could be well applied to understand the diseases and diagnostics.” - Dr. Elisa Wurmbach, Mount Sinai School of Medicine, New York

“Excellent mix of technology and scientific talks; an outstanding agenda.” - Fiona Stewart, Business Development, New England Biolabs

To view the details of 2003 meeting Sponsors, Posters, Awards, and Surveys please visit our main page and click After BioArrays-2003 Meeting information.